Sparks - OSE Immunotherapeutics

OSE Immunotherapeutics has received a second positive recommendation from the independent data monitoring committee (IDMC) to continue the Phase III ARTEMIA trial, without any modifications. This is the registrational programme investigating OSE’s lead cancer vaccine, Tedopi, in non-small cell lung cancer (NSCLC). As per this latest update, 163 patients had been randomised at the time of the meeting, with 152 included in the IDMC review. Patient recruitment remains on track to be complete by end-2026, before a primary endpoint readout in Q128.

ARTEMIA (which commenced in September 2024) is investigating Tedopi as a potential second-line monotherapy for NSCLC, after the use of immune checkpoint inhibitors as first-line treatments. The trial has been designed to randomise participants (expected n=363) two to one to receive either Tedopi or docetaxel (standard of care in the second-line setting).